• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Clinical evaluation of DIAGNOVIR SARS-CoV-2 ultra-rapid antigen test performance compared to PCR-based testing

tetano

Editor, Senior Moderator
Sci Rep


. 2023 Mar 17;13(1):4438.
doi: 10.1038/s41598-023-31177-8.
Clinical evaluation of DIAGNOVIR SARS-CoV-2 ultra-rapid antigen test performance compared to PCR-based testing


Ali Aytac Seymen[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Ezgi Gulten[SUP] #[/SUP][SUP] 4 [/SUP], Erol Ozgur[SUP] #[/SUP][SUP] 1 5 [/SUP], Bülend Ortaç[SUP] #[/SUP][SUP] 1 3 [/SUP], Irem Akdemir[SUP] 4 [/SUP], Gule Cinar[SUP] 4 [/SUP], Elif Mukime Saricaoglu[SUP] 4 [/SUP], Gulen Guney-Esken[SUP] 6 [/SUP], Erman Akkus[SUP] 7 [/SUP], Fusun Can[SUP] 8 6 [/SUP], Zeynep Ceren Karahan[SUP] 9 [/SUP], Alpay Azap[SUP] 4 [/SUP], Erkan Tuncay[SUP] 10 [/SUP]



Affiliations
Free PMC article

Abstract

Coronavirus Disease-19 (COVID-19) is a highly contagious infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The development of rapid antigen tests has contributed to easing the burden on healthcare and lifting restrictions by detecting infected individuals to help prevent further transmission of the virus. We developed a state-of-art rapid antigen testing system, named DIAGNOVIR, based on immune-fluorescence analysis, which can process and give the results in a minute. In our study, we assessed the performance of the DIAGNOVIR and compared the results with those of the qRT-PCR test. Our results demonstrated that the sensitivity and specificity of the DIAGNOVIR were 94% and 99.2%, respectively, with a 100% sensitivity and 96.97% specificity, among asymptomatic patients. In addition, DIAGNOVIR can detect SARS‑CoV‑2 with 100% sensitivity up to 5 days after symptom onset. We observed that the DIAGNOVIR Rapid Antigen Test's limit of detection (LoD) was not significantly affected by the SARS‑CoV‑2 variants including Wuhan, alpha (B1.1.7), beta (B.1.351), delta (B.1.617.2) and omicron (B.1.1.529) variants, and LoD was calculated as 8 × 10[SUP]2[/SUP], 6.81 × 10[SUP]1.5[/SUP], 3.2 × 10[SUP]1.5[/SUP], 1 × 10[SUP]3[/SUP], and 1 × 10[SUP]3.5[/SUP] TCID50/mL, respectively. Our results indicated that DIAGNOVIR can detect all SARS-CoV-2 variants in just seconds with higher sensitivity and specificity lower testing costs and decreased turnover time.
 
Back
Top Bottom